US · SPRC
SciSparc Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Tel Aviv 6971916
- Website
- scisparc.com
Price · as of 2024-12-31
$7.91
Market cap 288.91K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $39.50 | +399.37% |
| Intrinsic Value(DCF) | $2.69 | -65.99% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $47.57 | +501.4% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $1,938.30 | $812.84 | $7.59 | $0.00 | $0.00 |
| 2022 | $382.20 | $204.71 | $0.84 | $0.00 | $0.00 |
| 2023 | $70.98 | $242.26 | $16,140.36 | $0.00 | $0.00 |
| 2024 | $6.72 | $39.50 | $0.00 | $0.00 | $47.57 |
AI valuation
Our deep-learning model estimates SciSparc Ltd.'s (SPRC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $39.50
- Current price
- $7.91
- AI upside
- +399.37%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.69
-65.99% upside
Graham-Dodd
—
— upside
Graham Formula
$47.57
+501.4% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SPRC | SciSparc Ltd. | $7.91 | 288.91K | +399% | -66% | — | +501% | -5.24 | 4.80 | 29.97 | -5.32 | — | 5.86 | 38.74% | -560.18% | -481.16% | -94.77% | -166.78% | -69.41% | 0.01 | -243.87 | 5.36 | 5.02 | 0.21 | -9850.00% | -5464.00% | -1330.00% | -13.04% | -3.65 | -116.57% | 0.00% | 0.00% | 0.00% | -5.08 | -7.28 | 28.43 | 5.04 |
| ARTL | Artelo Biosciences, Inc. | $1.19 | 2.75M | — | — | — | — | -0.09 | -0.92 | — | -0.10 | -0.03 | -0.35 | 0.00% | — | — | -1625.11% | 4102.16% | -343.49% | -0.54 | -58.78 | 0.17 | 0.15 | -0.01 | 31049.00% | — | 204.00% | -726.31% | -2.11 | 3064.75% | 0.00% | 0.00% | 0.00% | -0.11 | -0.15 | — | -46.19 |
| INDP | Indaptus Therapeutics, In… | $2.06 | 3.61M | — | — | — | — | -14.39 | 54.78 | — | -13.69 | — | 54.78 | 0.00% | — | — | -187.52% | 1071.45% | -134.95% | 0.02 | — | 1.95 | 1.71 | 0.37 | -1250.00% | — | -807.00% | -5.70% | -3.63 | 859.29% | 0.00% | 0.00% | 0.00% | -13.69 | -17.07 | — | 20.29 |
| JSPR | Jasper Therapeutics, Inc. | $1.38 | 22.43M | — | — | — | — | -1.10 | 1.27 | — | -0.11 | — | 1.27 | 0.00% | — | — | -101.73% | 1104.03% | -81.55% | 0.03 | — | 4.98 | 4.70 | 0.93 | -2087.00% | — | 2067.00% | -80.64% | -4.11 | 914.55% | 0.00% | 0.00% | 0.00% | -0.11 | -0.13 | — | -3.88 |
| ONCO | Onconetix, Inc. | $0.67 | 381.85K | +297,429% | +1,069% | — | — | -0.01 | 0.07 | 0.25 | -0.16 | 0.00 | -0.04 | 41.80% | -2237.96% | -2325.21% | -2928.31% | -611.88% | -101.45% | 0.98 | -40.13 | 0.05 | 0.04 | -0.15 | 198134.00% | 421731.00% | -2282.00% | -1666.65% | -0.57 | -116.03% | 32.69% | -0.40% | 32.80% | -0.17 | -0.90 | 3.74 | -12.99 |
| PTIX | Protagenic Therapeutics, … | $0.47 | 896.47K | — | — | — | — | -4.00 | 21.80 | — | -3.70 | — | 21.80 | 0.00% | — | — | -236.06% | 939.82% | -175.99% | 0.00 | — | 2.00 | 1.95 | 0.34 | -174.00% | — | 942.00% | -19.09% | -4.47 | 695.10% | 0.00% | 0.00% | 2.49% | -3.55 | -4.80 | — | -20.97 |
| SCNI | Scinai Immunotherapeutics… | $0.89 | 1.17M | — | — | — | — | 0.58 | 0.28 | 4.25 | -0.42 | — | 0.28 | -88.15% | -1312.77% | 728.88% | 177.37% | -81.41% | 31.02% | 0.21 | -6.00 | 1.32 | 1.21 | -0.02 | -13571.00% | — | -3665.00% | -226.90% | -3.51 | -59.82% | 0.00% | 0.00% | 556.57% | -0.34 | -0.46 | 4.44 | -13.77 |
| SLRX | Salarius Pharmaceuticals,… | $0.84 | 4.92M | — | — | — | — | -0.18 | 0.67 | — | 0.21 | 0.00 | 0.67 | 0.00% | — | — | -164.02% | 1120.04% | -116.05% | 0.15 | — | 1.98 | 1.61 | 0.40 | 15226842.00% | — | -6477.00% | -445.68% | -2.99 | 883.90% | 0.00% | 0.00% | 0.00% | 0.21 | 0.26 | — | -43.21 |
| SLXN | Silexion Therapeutics Ltd… | $1.73 | 967.66K | — | — | — | — | -7.53 | -31.20 | — | -7.75 | — | -31.20 | 0.00% | — | — | 169.73% | 122.14% | -406.92% | -1.13 | -241.75 | 0.64 | 0.34 | -0.20 | -4027.00% | — | 8538.00% | -6.76% | -2.38 | 81.79% | 0.00% | 0.00% | 0.00% | -10.16 | -15.18 | — | -25.28 |
About SciSparc Ltd.
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
- CEO
- Oz Adler
- Employees
- 2
- Beta
- 1.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.69 ÷ $7.91) − 1 = -65.99% (DCF, example).